Abbott Laboratories (ABT)
NYSE: ABT
· Real-Time Price · USD
131.48
2.20 (1.70%)
At close: Aug 15, 2025, 12:30 PM
Abbott Laboratories Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 13.5B | 13.4B | 5.77B | 5.56B | 5.63B | 5.72B | 5.16B | 5.16B | 5.8B | 6.93B | 7.89B | 8.55B | 7.72B | 7.07B | 7.24B | 6.38B | 5.72B |
Depreciation & Amortization | 3.17B | 3.22B | 3.22B | 3.25B | 3.24B | 3.24B | 3.24B | 3.23B | 3.25B | 3.27B | 3.34B | 3.38B | 3.43B | 3.54B | 3.52B | 3.48B | 3.43B |
Stock-Based Compensation | 658M | 673M | 676M | 676M | 667M | 644M | 645M | 651M | 661M | 685M | 676M | 667M | 657M | 640M | 632M | 618M | 601M |
Other Working Capital | -8.47B | -8.47B | -1.89B | -2.07B | -2.73B | -3.8B | -1.95B | -1.7B | -951M | -80M | -1.26B | -1.37B | -1.56B | 8B | 7.98B | 15.15B | 21.51B |
Other Non-Cash Items | 794M | 482M | 1.41B | 1.25B | 454M | 1.2B | -582M | -332M | 328M | 328M | 266M | 195M | 195M | 189M | 377M | 624M | 788M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -9.17B | -9.22B | -2.35B | -2.83B | -2.85B | -3.55B | -1.91B | -1.26B | -1.38B | -1.63B | -1.85B | -2.55B | -2.04B | -905M | -510M | -471M | -723M |
Operating Cash Flow | 8.95B | 8.56B | 8.73B | 7.9B | 7.14B | 7.26B | 6.55B | 7.45B | 8.66B | 9.58B | 10.32B | 10.24B | 9.96B | 10.53B | 11.26B | 10.63B | 9.82B |
Capital Expenditures | -2.29B | -2.21B | -2.24B | -2.25B | -2.22B | -2.2B | -2.06B | -1.96B | -1.84B | -1.78B | -1.78B | -1.77B | -1.81B | -1.89B | -1.95B | -1.99B | -2.21B |
Cash Acquisitions | n/a | n/a | n/a | -51M | -837M | -837M | -837M | -786M | 48M | 48M | -86M | -172M | -172M | -187M | -111M | -25M | -57M |
Purchase of Investments | n/a | n/a | -114M | -152M | -73M | -159M | -45M | -10M | -48M | -3M | -176M | -200M | -227M | -200M | -110M | -83M | -97M |
Sales Maturities Of Investments | n/a | n/a | 43M | 81M | 788M | 788M | 745M | 707M | n/a | n/a | 77M | -4M | 77M | 77M | 10M | 91M | 10M |
Other Investing Acitivies | -90M | -131M | 17M | 32M | -754M | -723M | -747M | -738M | -6M | -8M | 187M | 205M | 185M | 187M | 93M | 113M | 114M |
Investing Cash Flow | -2.38B | -2.34B | -2.3B | -2.34B | -3.1B | -3.13B | -2.94B | -2.79B | -1.84B | -1.74B | -1.78B | -1.95B | -1.95B | -2.01B | -2.07B | -1.89B | -2.24B |
Debt Repayment | -1.45B | -537M | -863M | -2.41B | -2.56B | -2.48B | -1.53B | 4M | 2M | -699M | -905M | -996M | -1.01B | -248M | -53M | -1.34B | -78M |
Common Stock Repurchased | -1.35B | -1.29B | -1.24B | -490M | -913M | -1.23B | -1.65B | -2.45B | -2.03B | -3.79B | -4.08B | -3.87B | -4.33B | -2.3B | -1.49B | -909M | -442M |
Dividend Paid | -3.9B | -3.84B | -3.77B | -3.69B | -3.62B | -3.56B | -3.49B | -3.43B | -3.37B | -3.31B | -3.28B | -3.26B | -3.23B | -3.2B | -3.04B | -2.88B | -2.72B |
Other Financial Acitivies | 417M | 264M | 273M | 237M | 239M | 167M | 174M | 175M | 170M | 167M | 208M | 221M | 228M | 255M | 189M | 202M | 231M |
Financial Cash Flow | -6.28B | -5.4B | -5.59B | -6.36B | -6.86B | -7.09B | -6.5B | -5.7B | -5.22B | -7.64B | -8.06B | -7.9B | -8.35B | -5.49B | -4.39B | -4.93B | -3.01B |
Net Cash Flow | 248M | 720M | 849M | -848M | -2.88B | -2.99B | -2.88B | -1.1B | 1.49B | 83M | 292M | 279M | -379M | 2.96B | 4.82B | 3.9B | 4.68B |
Free Cash Flow | 6.66B | 6.35B | 6.49B | 5.65B | 4.92B | 5.06B | 4.49B | 5.49B | 6.82B | 7.8B | 8.54B | 8.47B | 8.15B | 8.65B | 9.31B | 8.64B | 7.61B |